A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

Discover why private ingrown hairs pose more than cosmetic concerns, including infection risks, and learn 6 effective solutions from dermatologists.

In the case described in the Equine Veterinary Education Journal, x-rays and hoof testers were not able to predict the location of a subsolar abscess in this horse's foot ...

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

Tasman District Council imposed the classification after receiving a report in August last year that Boy had attacked another ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

The cause of most concern are seed oils - a type of vegetable oil derived from plant seeds but the cause of most concern are ...

Eventual Australian Survivor: All Stars winner David Genat didn’t have an easy run to landing the title of Sole Survivor. The ...